OATP1B1/1B3 deficiency exacerbates hyperbilirubinemia in erythropoietic protoporphyria
- PMID: 40540978
- DOI: 10.1016/j.dmd.2025.100105
OATP1B1/1B3 deficiency exacerbates hyperbilirubinemia in erythropoietic protoporphyria
Abstract
Erythropoietic protoporphyria (EPP) is caused by loss-of-function mutations in ferrochelatase (FECH), leading to the accumulation of its substrate, protoporphyrin IX (PPIX). PPIX is primarily produced in the bone marrow and transported to the liver for excretion. Because PPIX is hydrophobic, its elevated levels can cause bile duct blockage, cholestatic liver injury, and even liver failure. However, the specific transporter responsible for PPIX uptake into hepatocytes remains unclear. The OATP1B1/1B3 transporters, which are expressed in hepatocytes, facilitate the uptake of coproporphyrin III, a structural analog of PPIX. Additionally, OATP1B1/1B3 mediates the uptake of bilirubin, a biomarker of liver injury, from plasma into the liver for excretion. Therefore, we aimed to determine the role of OATP1B1/1B3 in regulating PPIX and bilirubin homeostasis under EPP conditions. A mouse strain carrying a Fech mutation was used as an EPP model. Building on this, we generated a new EPP mouse model with Oatp1a/1b deficiency. Using these EPP mouse models, along with OATP1B1/1B3-overexpressing cells, our study revealed that PPIX is not a substrate of OATP1B1/1B3. Notably, our work found that genetic deficiency or pharmacologic suppression of Oatp1a/1b exacerbates hyperbilirubinemia in EPP mice without worsening liver injury. Mechanistically, Oatp1a/1b deficiency impairs bilirubin uptake from plasma, while Fech deficiency leads to PPIX-mediated bile duct blockage and reduced bilirubin excretion, synergistically exacerbating hyperbilirubinemia. In summary, our work demonstrated that deficiency or suppression of Oatp1a/1b exacerbates hyperbilirubinemia in EPP mouse models, suggesting that assessment of OATP1B1/1B3 function is crucial in EPP patients with EPP with hyperbilirubinemia. SIGNIFICANCE STATEMENT: This work revealed that serum bilirubin levels are not paralleled with liver damage in the erythropoietic protoporphyria mouse models with Oatp1a/1b deficiency. Our findings suggest that assessment of OATP1B1/1B3 function is crucial in patients with erythropoietic protoporphyria with hyperbilirubinemia.
Keywords: Bilirubin; Liver diseases; OATPs; Protoporphyrin IX.
Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest The authors have no conflicts to report.
Similar articles
-
Characterization of organic anion transporting polypeptide (OATP)1B1 and OATP1B3 humanized rat as a translational model to study the pharmacokinetics of OATP1B substrate drugs.Drug Metab Dispos. 2025 Jul;53(7):100101. doi: 10.1016/j.dmd.2025.100101. Epub 2025 Jun 2. Drug Metab Dispos. 2025. PMID: 40554317
-
Effects of iron supplements in individuals with erythropoietic protoporphyria.Photodiagnosis Photodyn Ther. 2024 Jun;47:104211. doi: 10.1016/j.pdpdt.2024.104211. Epub 2024 May 9. Photodiagnosis Photodyn Ther. 2024. PMID: 38734198
-
Coproporphyrin I as an in vitro fluorescent probe to measure OATP1B1 transport activity.Drug Metab Dispos. 2025 May;53(5):100073. doi: 10.1016/j.dmd.2025.100073. Epub 2025 Mar 27. Drug Metab Dispos. 2025. PMID: 40319557
-
Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen.Cancer Res Commun. 2024 Sep 1;4(9):2489-2497. doi: 10.1158/2767-9764.CRC-24-0332. Cancer Res Commun. 2024. PMID: 39207193 Free PMC article.
-
Inherited genetic late-onset erythropoietic protoporphyria: A systematic review of the literature.Photodermatol Photoimmunol Photomed. 2021 Sep;37(5):374-379. doi: 10.1111/phpp.12667. Epub 2021 Feb 21. Photodermatol Photoimmunol Photomed. 2021. PMID: 33556208
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical